Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (vol 27, pg 802, 2021)

NATURE MEDICINE

Volume 27, Issue 10, Pages 1849-1849

NATURE PORTFOLIO

-

Biochemistry & Molecular Biology Cell Biology Medicine, Research & Experimental

1. Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence and program
2. Kohlberg Chair at Harvard Medical School
3. Trust Family
4. Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute
5. National Cancer Institute
6. NCI [P50 CA101942, U01 CA236489]
7. Department of Defense